• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Pharmacokinetic and microbial susceptibility studies of ceftriaxone.

作者信息

Baumgartner J D, Glauser M P

出版信息

Eur J Clin Microbiol. 1983 Oct;2(5):501-4. doi: 10.1007/BF02013916.

DOI:10.1007/BF02013916
PMID:6315426
Abstract

The in vitro activity of ceftriaxone, a new parenteral cephalosporin, was tested against 450 strains isolated from blood cultures and compared with that of various other antibiotics. The compound was comparable to cefotaxime for all species tested. It was more potent than cefoperazone, cefamandole and ticarcillin in inhibiting Enterobacteriaceae (Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, indole-positive Proteus spp. and Serratia marcescens). The MIC95 of ceftriaxone for these strains was 0.5 microgram/ml. The drug was less active against Staphylococcus aureus than cefamandole, cloxacillin and vancomycin, but most isolates were inhibited by 4 micrograms/ml. Against Pseudomonas aeruginosa, ceftriaxone was comparable in activity to ticarcillin (MIC95 = 64 micrograms/ml), and inferior to cefoperazone, ceftazidime and cefsulodine. Levels of ceftriaxone in serum and various body fluids were determined by bio-assays. Due to its very long half-life (8 h), ceftriaxone serum levels 24 h after i.v. or i.m. injection of 1 and 2 g were still above the MIC95 of all strains tested except Pseudomonas aeruginosa. Levels in bile, synovial and cerebro-spinal fluids were high.

摘要

相似文献

1
Pharmacokinetic and microbial susceptibility studies of ceftriaxone.
Eur J Clin Microbiol. 1983 Oct;2(5):501-4. doi: 10.1007/BF02013916.
2
In vitro activity of ceftazidime and ceftriaxone.头孢他啶和头孢曲松的体外活性。
Clin Ther. 1983;5(6):603-16.
3
The in vitro antibacterial activity of ceftriaxone in comparison with nine other antibiotics.头孢曲松与其他九种抗生素相比的体外抗菌活性。
Curr Med Res Opin. 1985;9(7):480-93. doi: 10.1185/03007998509109622.
4
Ceftriaxone: in vitro activity against 410 bacterial isolates compared with cefotaxime.头孢曲松:与头孢噻肟相比,对410株细菌分离株的体外活性。
Infection. 1982 Sep-Oct;10(5):307-9. doi: 10.1007/BF01640881.
5
Ceftriaxone: a summary of in vitro antibacterial qualities including recommendations for susceptibility tests with 30-micrograms disks.
Diagn Microbiol Infect Dis. 1983 Dec;1(4):295-311. doi: 10.1016/0732-8893(83)90005-6.
6
[Patterns of resistance of Staph aureus and gram-negative bacteria to aminoglycosides and cephalosporins].[金黄色葡萄球菌和革兰氏阴性菌对氨基糖苷类和头孢菌素类的耐药模式]
Wiad Lek. 1989 May 1;42(9):579-83.
7
Comparative in vitro activity of ceftriaxone against clinical bacterial isolates in Nigeria.
Chemotherapy. 1985;31(2):130-7. doi: 10.1159/000238325.
8
[Comparative study of ceftriaxone, cefotaxime and moxalactam against 150 Gram negative strains (author's transl)].头孢曲松、头孢噻肟和拉氧头孢对150株革兰氏阴性菌的比较研究(作者译)
Pathol Biol (Paris). 1982 Jun;30(6):341-4.
9
The in-vitro activity of ceftazidime compared with that of other cephalosporins.头孢他啶与其他头孢菌素的体外活性比较。
J Antimicrob Chemother. 1981 Sep;8 Suppl B:47-51. doi: 10.1093/jac/8.suppl_b.47.
10
An in-vitro comparison of new cephalosporins with special reference to Pseudomonas aeruginosa.新型头孢菌素的体外比较,特别涉及铜绿假单胞菌。
J Antimicrob Chemother. 1981 Sep;8 Suppl B:97-105. doi: 10.1093/jac/8.suppl_b.97.

引用本文的文献

1
The potential uses of ceftriaxone.头孢曲松的潜在用途。
Eur J Clin Microbiol. 1983 Oct;2(5):485-8. doi: 10.1007/BF02013913.
2
Biliary excretion and pharmacokinetics of ceftriaxone after cholecystectomy.胆囊切除术后头孢曲松的胆汁排泄及药代动力学
Eur J Clin Pharmacol. 1986;30(4):445-51. doi: 10.1007/BF00607958.

本文引用的文献

1
Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin.头孢曲松(Ro 13 - 9904)的抗菌活性,一种对β-内酰胺酶稳定的头孢菌素。
Antimicrob Agents Chemother. 1981 Mar;19(3):414-23. doi: 10.1128/AAC.19.3.414.
2
In vitro antibacterial activity and susceptibility of the cephalosporin Ro 13-9904 to beta-lactamases.头孢菌素Ro 13-9904对β-内酰胺酶的体外抗菌活性及敏感性
Antimicrob Agents Chemother. 1980 Aug;18(2):292-8. doi: 10.1128/AAC.18.2.292.
3
In vitro evaluation of Ro 13-9904.Ro 13-9904的体外评估
Antimicrob Agents Chemother. 1980 Oct;18(4):574-8. doi: 10.1128/AAC.18.4.574.
4
Single daily dose treatment of severe refractory infections with ceftriaxone. Cost savings and possible parenteral outpatient treatment.每日单次剂量使用头孢曲松治疗严重难治性感染。节省成本及可能的门诊胃肠外治疗。
Arch Intern Med. 1983 Oct;143(10):1868-73.
5
Pharmacokinetics of ceftriaxone in humans.头孢曲松在人体内的药代动力学。
Antimicrob Agents Chemother. 1981 Nov;20(5):634-41. doi: 10.1128/AAC.20.5.634.
6
Comparative in vitro studies of Ro 13-9904, a new cephalosporin derivative.新型头孢菌素衍生物Ro 13-9904的体外比较研究
Antimicrob Agents Chemother. 1981 Mar;19(3):435-42. doi: 10.1128/AAC.19.3.435.